Biologic Technologies Limited

This project will pioneer a new approach to making viral vectors --- the essential building blocks for many advanced therapies --- by combining precision small-scale manufacturing with world-class molecular measurement. It brings together BiologIC Technologies, developer of the Qudos personal biomanufacturing system, and the National Measurement Laborator...

Patients suffering from genetic conditions continue to wait for the promise of cell and gene therapies to be realised. The major bottleneck for access to therapies is the cost of goods, largely comprising manufacturing costs arising from process inefficiencies. Viral vectors, particularly adeno-associated viruses (AAV), are pivotal in the production of ce...

At BiologIC Technologies we are developing an automated bioprocessing platform that is a highly integrated, modular and configurable system for developing advanced biology products such as therapies. Our current focus revolves around providing bioprocessing solutions for diverse fields, including cell and gene therapies, RNA applications, monoclonal antib...

ADC is an emerging class of advanced precision biotherapeutics that utilize antibodies to target specific drug payloads to specific cells or tissues. iProgen has been involved in ADC discovery and development for the past 9 years, partnering with multiple industry and academic institutions. Initially concentrating on oncology, ADC has expanded to non-onco...

A major focus of synthetic biology has been on programmable genetic regulatory systems to control gene expression. However, in the past years the attention has turned to RNA regulators as well for this task because of their versatility and the emergence of powerful new RNA design principles. The use of RNA regulators has been proven effective in numerous ...

RNA therapeutics will change the standard of care for many diseases, transitioning from rare to chronic diseases, and actualize personalized medicine for millions of patients. Demand for flexible cGMP manufacturing will significantly increase across multiple RNA-therapy modalities to accelerate their route-to-patient and improve their economics. However, ...

BiologIC is the inventor of the biocomputer, a highly integrated and programmable automation platform for producing bio-based products and data on demand. The biocomputer processes components of biological origin, such as cells, nucleic acids, proteins, and biological reagents, into useful products such as therapies. The biocomputer platform can run multi...

RNA therapeutics will change the standard of care for many diseases, transitioning from rare to chronic diseases, and actualize personalized medicine for millions of patients. Advances in generating, purifying and delivery of RNA mean drugs can be cost-effective and target new pathways. As a disruptive therapeutic technology, small research groups and bio...

BiologIC Technologies is developing the first world's biocomputer leveraging foundational IP and the latest additive manufacturing (3D printing) technologies. The first generation of the biocomputer is being developed to advance applications in diagnostics, advanced therapies, new vaccines and cultured meat and is designed to power the next generation of ...

One of the greatest challenges faced by humanity is to eliminate the existential threat of infectious diseases including zoonotic pandemics such as the threat of a future Disease X. The UK has a once-in-a-generation opportunity to create a long-term legacy from its COVID19 investments to build a world-leading industry that allows humanity to mitigate, or ...

The Aviation Biosafety Sensing System (ABSS) will develop a pathogen detection system that may be deployed in-flight as a portable module and subsequently integrated into aviation environmental conditioning systems. ABSS increases biosafety, passenger confidence and creates novel value from biosafety data. The system may also be implemented pre-flight (pr...

Humanity faces three enormous challenges: feeding 9.8 billion people by 2050, mitigating climate change and eliminating the existential threat of diseases including zoonotic pandemics. BiologIC is developing the world's first biocomputer. BiologIC's ambition is to build a world leading UK biocomputing industry to unleash the full potential of synthetic bi...